Navigation Links
Chiltern Welcomes Cedric Burg And James Gunter

LONDON and WILMINGTON, N.C., Dec. 10, 2012 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced that Dr. Cedric Burg and James Gunter have joined Chiltern, bringing their expertise in clinical research to serve our clients' needs and to strengthen our Global Clinical Development services.

"It gives me great pleasure to announce that Dr. Cedric Burg has been appointed to the position of Vice President, Global Clinical Development, Americas," stated Aize Smink, Chief Operating Officer, Chiltern. "Cedric will head Chiltern's Global Clinical Development business in the Americas, where he will lead our teams in Latin and North America to continue the expansion of our services and capabilities. We believe that Cedric's international experience and exposure to both pharma and CROs will be of great value to our clients in the US and ROW."

Recently joining Chiltern is James Gunter as Director of Dedicated Biometrics Services. "I am pleased to announce James Gunter as an addition to our Chiltern Biometrics team," commented Alecia Barbee, Vice President, Global Biometrics, Chiltern. "James will head up the Biometrics FSPs globally, where his industry experience and client focus will lead this team in continued growth."

Dr. Cedric Burg has more than 17 years experience in the clinical research field and has a truly international profile having held global senior roles within both a CRO environment and Pharma. He holds a Master's degree in Life and Health Sciences from the Universite de Rennes I, France, and a doctorate in Molecular and Cellular Biology from the Universite de Nantes, France, and will be based out of Wilmington, NC, US.

James Gunter brings 16 years in life sciences experience, including 12 years in operational and management roles in the CRO industry. He has spent most of his career leading Biometrics and Information Technology teams globally in the Americas, Europe and Asia. In these roles, he has been responsible for building teams and implementing processes and technologies that improve the efficiency and quality of clinical trials. James is field-based in the US.

Company profileAbout Chiltern:Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs nearly 1,400 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: For More Information Contact:Natalie Chong

Susan OjanenMarketing Director

Marketing ExecutiveChiltern International Ltd.

Chiltern International Inc.171 Bath Road

1241 Volunteer ParkwaySlough

Suite 950Berkshire SL1 4AA


USATel:  +44 (0) 1753 512 000

Tel:  +1 (423) 968

SOURCE Chiltern
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Chiltern Wins CRO Leadership Award From Life Science Leader
2. The CNIO welcomes the new academic year with a spotlight on cancer genetics
3. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board
4. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
5. EMBO welcomes 55 leading life scientists as members
Post Your Comments:
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... , May 12, 2016 , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology: